Novartis, Index et al. lead €32m series-A for GenSight Biologics

GenSight Biologics will use its series-A funding to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP). The company's lead product is expected to enter clinical stages in 2013.

Company
GenSight Biologics is a biotech company based at the Vision Institute in Paris. The business was founded in 2011 and develops gene therapy-based treatments of retinal degenerative diseases.

Its co-founders, José Sahel, Botond Roska, Ernst Bamberg, Jean Bennett, Luk Vandenberghe and Connie Cepko, are all experts in this field of medical diagnostics.

People
Florent Gros of Novartis, Genghis Lloyd-Harris of Abingworth and Guido Magni of Versant will join the company's board of directors.
 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Index Ventures